STOCK TITAN

[Form 4] Catheter Precision, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Catheter Precision, Inc. (VTAK) reported an insider transaction in which a company director was granted 50,000 stock options with an exercise price of $0.18. The options were granted on the reported transaction date and vest one-third each year beginning on the first anniversary of the grant. The options are exercisable through the expiration date in 2035, and the reporting person holds 50,000 underlying shares post-transaction.

This disclosure is a routine director equity award that creates long-term option-based compensation and the right to acquire 50,000 shares at the stated strike price subject to the vesting schedule.

Catheter Precision, Inc. (VTAK) ha segnalato un'operazione interna in cui un amministratore della società ha ricevuto 50.000 opzioni su azioni con prezzo di esercizio pari a $0,18. Le opzioni sono state concesse nella data indicata e maturano per un terzo ogni anno a partire dal primo anniversario della concessione. Le opzioni sono esercitabili fino alla scadenza nel 2035 e, dopo l'operazione, la persona che ha effettuato la comunicazione detiene 50.000 azioni sottostanti.

Si tratta di una consueta assegnazione azionaria per un membro del consiglio, che rappresenta una retribuzione a lungo termine basata su opzioni e il diritto di acquisire 50.000 azioni al prezzo indicato, secondo il calendario di maturazione.

Catheter Precision, Inc. (VTAK) informó una operación interna en la que un miembro del consejo recibió 50.000 opciones sobre acciones con un precio de ejercicio de $0,18. Las opciones se concedieron en la fecha comunicada y consolidan un tercio cada año a partir del primer aniversario de la concesión. Las opciones pueden ejercitarse hasta la fecha de vencimiento en 2035, y la persona informante posee 50.000 acciones subyacentes tras la operación.

Es una concesión habitual de acciones a un director, que constituye una compensación a largo plazo basada en opciones y el derecho a adquirir 50.000 acciones al precio indicado, sujeto al calendario de adquisición.

Catheter Precision, Inc. (VTAK)는 회사 이사가 $0.1850,000 주식 옵션을 부여받았다는 내부 거래를 보고했습니다. 옵션은 보고된 거래일에 부여되었으며 부여일 1주년부터 매년 1/3씩 권리가 취득됩니다. 이 옵션은 2035년에 만료되는 시점까지 행사할 수 있으며, 보고인은 거래 후 기초 주식 50,000주를 보유하고 있습니다.

이는 이사회 구성원에게 통상적으로 부여되는 주식보상으로, 장기 옵션 기반 보수에 해당하며 명시된 행사가격으로 50,000주를 취득할 권리를 조건부로 제공합니다.

Catheter Precision, Inc. (VTAK) a signalé une transaction d’initié dans laquelle un administrateur de la société s'est vu attribuer 50 000 options d'achat d'actions au prix d'exercice de 0,18 $. Les options ont été accordées à la date déclarée et acquièrent droit au tiers chaque année à compter du premier anniversaire de l'attribution. Les options sont exerçables jusqu'à la date d'expiration en 2035, et la personne déclarante détient 50 000 actions sous-jacentes après la transaction.

Il s'agit d'une attribution courante d'actions à un administrateur, constituant une rémunération à long terme fondée sur des options et le droit d'acquérir 50 000 actions au prix indiqué, sous réserve du calendrier d'acquisition des droits.

Catheter Precision, Inc. (VTAK) meldete eine Insider-Transaktion, bei der ein Firmenvorstand 50.000 Aktienoptionen mit einem Ausübungspreis von $0,18 erhalten hat. Die Optionen wurden am gemeldeten Transaktionsdatum gewährt und werden zu je einem Drittel jährlich ab dem ersten Jahrestag der Gewährung unverfallbar. Die Optionen sind bis zum Verfallsdatum im Jahr 2035 ausübbar, und die meldepflichtige Person hält nach der Transaktion 50.000 zugrundeliegende Aktien.

Dabei handelt es sich um eine routinemäßige Gewährung von Aktien an ein Vorstandsmitglied, die als langfristige, optionsbasierte Vergütung gilt und das Recht gewährt, 50.000 Aktien zum angegebenen Ausübungspreis entsprechend dem Vesting-Zeitplan zu erwerben.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine director option grant; modest in size, long-dated, and structured with multi-year vesting.

The grant of 50,000 options at a $0.18 exercise price is a standard mechanism to align a director's interests with shareholders. Vesting one-third per year encourages continued service. The long-term expiration through 2035 provides extended upside potential for the holder but delays full potential dilution until vested and exercised. Based solely on the filing, the transaction appears procedural and not immediately material to capital structure.

TL;DR: Governance-standard equity award to a director with time-based vesting; transparency maintained via Form 4 disclosure.

The Form 4 reports an option award with clear vesting terms: 1/3 per year starting after one year, and an expiration date in 2035. This structure supports retention and aligns incentives without immediate share issuance. The filing fulfills Section 16 disclosure requirements and provides investors with the necessary details to assess director compensation timing and potential future share issuance.

Catheter Precision, Inc. (VTAK) ha segnalato un'operazione interna in cui un amministratore della società ha ricevuto 50.000 opzioni su azioni con prezzo di esercizio pari a $0,18. Le opzioni sono state concesse nella data indicata e maturano per un terzo ogni anno a partire dal primo anniversario della concessione. Le opzioni sono esercitabili fino alla scadenza nel 2035 e, dopo l'operazione, la persona che ha effettuato la comunicazione detiene 50.000 azioni sottostanti.

Si tratta di una consueta assegnazione azionaria per un membro del consiglio, che rappresenta una retribuzione a lungo termine basata su opzioni e il diritto di acquisire 50.000 azioni al prezzo indicato, secondo il calendario di maturazione.

Catheter Precision, Inc. (VTAK) informó una operación interna en la que un miembro del consejo recibió 50.000 opciones sobre acciones con un precio de ejercicio de $0,18. Las opciones se concedieron en la fecha comunicada y consolidan un tercio cada año a partir del primer aniversario de la concesión. Las opciones pueden ejercitarse hasta la fecha de vencimiento en 2035, y la persona informante posee 50.000 acciones subyacentes tras la operación.

Es una concesión habitual de acciones a un director, que constituye una compensación a largo plazo basada en opciones y el derecho a adquirir 50.000 acciones al precio indicado, sujeto al calendario de adquisición.

Catheter Precision, Inc. (VTAK)는 회사 이사가 $0.1850,000 주식 옵션을 부여받았다는 내부 거래를 보고했습니다. 옵션은 보고된 거래일에 부여되었으며 부여일 1주년부터 매년 1/3씩 권리가 취득됩니다. 이 옵션은 2035년에 만료되는 시점까지 행사할 수 있으며, 보고인은 거래 후 기초 주식 50,000주를 보유하고 있습니다.

이는 이사회 구성원에게 통상적으로 부여되는 주식보상으로, 장기 옵션 기반 보수에 해당하며 명시된 행사가격으로 50,000주를 취득할 권리를 조건부로 제공합니다.

Catheter Precision, Inc. (VTAK) a signalé une transaction d’initié dans laquelle un administrateur de la société s'est vu attribuer 50 000 options d'achat d'actions au prix d'exercice de 0,18 $. Les options ont été accordées à la date déclarée et acquièrent droit au tiers chaque année à compter du premier anniversaire de l'attribution. Les options sont exerçables jusqu'à la date d'expiration en 2035, et la personne déclarante détient 50 000 actions sous-jacentes après la transaction.

Il s'agit d'une attribution courante d'actions à un administrateur, constituant une rémunération à long terme fondée sur des options et le droit d'acquérir 50 000 actions au prix indiqué, sous réserve du calendrier d'acquisition des droits.

Catheter Precision, Inc. (VTAK) meldete eine Insider-Transaktion, bei der ein Firmenvorstand 50.000 Aktienoptionen mit einem Ausübungspreis von $0,18 erhalten hat. Die Optionen wurden am gemeldeten Transaktionsdatum gewährt und werden zu je einem Drittel jährlich ab dem ersten Jahrestag der Gewährung unverfallbar. Die Optionen sind bis zum Verfallsdatum im Jahr 2035 ausübbar, und die meldepflichtige Person hält nach der Transaktion 50.000 zugrundeliegende Aktien.

Dabei handelt es sich um eine routinemäßige Gewährung von Aktien an ein Vorstandsmitglied, die als langfristige, optionsbasierte Vergütung gilt und das Recht gewährt, 50.000 Aktien zum angegebenen Ausübungspreis entsprechend dem Vesting-Zeitplan zu erwerben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
COLOMBATTO MARTIN J

(Last) (First) (Middle)
1670 HIGHWAY 160 WEST
SUITE 205

(Street)
FORT MILL SC 29708

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Catheter Precision, Inc. [ VTAK ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Options (Right to Buy) $0.18 08/12/2025 A 50,000 (1) 08/12/2035 Common Stock 50,000 $0 50,000 D
Explanation of Responses:
1. Options vests 1/3 per year beginning on first anniversary of grant date.
/s/ Martin Colombatto 08/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Catheter Precision

NYSE:VTAK

VTAK Rankings

VTAK Latest News

VTAK Latest SEC Filings

VTAK Stock Data

3.98M
609.87k
7.99%
4.89%
2.93%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
FORT MILL